![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
HealthTree's ASH 2023 Myeloma Summary
Over the past two months, we've been covering important information presented at one of the biggest myeloma academic conferences of the year. We are now concluding our coverage of this important event.
The 65th annual American Society of Hematology (ASH) Conference brought us a lot of important data regarding how patient populations are responding to treatment, the influence of novel treatments like CAR-T and bispecific antibody therapy, how patients and caregivers can improve their quality of life, and more.
I'm grateful to my team: Beth Travis, Diane Kennedy, Todd Kennedy, Bonnie Falbo, Valarie Traynham, and Rozalynn Hite, who worked many hours to make this research available and understandable to you. Enjoy!
To read what we covered from this past year's ASH conference, read below:
General ASH 2023 Articles
Bispecific Antibody Therapy Articles
An Indirect Comparison of Elranatamab and Teclistamab
How Tocilizumab Prevents CRS with Teclistamab Administration
How Do We Apply T-Cell Redirection for Myeloma? Part 1: Bispecific Antibody Therapies
Bispecific Therapy for High-Risk Smoldering Myeloma
CAR-T Therapy Articles
Raising the BCMA Standard in Multiple Myeloma
The Risk of Secondary Cancers with CAR-T Therapy
The Next Frontier in CAR T-Cell Therapy- GPRC5D: Auto & Allo in the Spotlight
The Effect of Stem Cell Infusion on ICAHT after CAR-T Cell Therapy
Understanding Myeloma Progression, Relapse, and Survival Probability Articles
T-Cell Exhaustion Predicts Early Relapse after SCT in Myeloma
Can You Slow Your Myeloma Progression by Eating a Plant-Based Diet?
Dynamic Frailty Status Could Provide Better Prediction of Survival Probability
Minimal Residual Disease in Myeloma Articles
What Do Myeloma Patients Think About MRD Testing?
Financial and Quality of Life Articles
How Financial Toxicity is Affecting Myeloma Patients and Their Families
Downshifting to Upshift: Changing the Way We Think
Caregiver Distress – How Are You, REALLY?
How Your Insurance Type May Affect Your Blood Cancer Outcome
Finding Renewed Purpose with Myeloma
How Willing Are Black Myeloma Patients to Participate in Clinical Trials?
Groundbreaking Research on Myeloma Treatments
Down with Dex! New Research Reveals Dexamethasone Dosing Can Be Reduced
Using Venetoclax with 11;14 Myeloma Patients
How Can Relapsed/Refractory Myeloma Outcomes Improve in 2024?
Real-World Velcade Prescribing Patterns and Outcomes in Newly Diagnosed Multiple Myeloma
Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma
High-Risk Smoldering and Active Myeloma Response Articles
How Extramedullary and High-Risk Myeloma Patients Are Responding to Immunotherapy
High-Risk Smoldering Myeloma: To Treat or Not to Treat?
ASH 2023 Resources
Would you like to watch ASH 2023 myeloma research interviews from the investigators themselves? Click "ASH 2023" here: HealthTree University Conference Coverage
To read all of the ASH 2023 articles, click here: HealthTree 2023 ASH Articles
Over the past two months, we've been covering important information presented at one of the biggest myeloma academic conferences of the year. We are now concluding our coverage of this important event.
The 65th annual American Society of Hematology (ASH) Conference brought us a lot of important data regarding how patient populations are responding to treatment, the influence of novel treatments like CAR-T and bispecific antibody therapy, how patients and caregivers can improve their quality of life, and more.
I'm grateful to my team: Beth Travis, Diane Kennedy, Todd Kennedy, Bonnie Falbo, Valarie Traynham, and Rozalynn Hite, who worked many hours to make this research available and understandable to you. Enjoy!
To read what we covered from this past year's ASH conference, read below:
General ASH 2023 Articles
Bispecific Antibody Therapy Articles
An Indirect Comparison of Elranatamab and Teclistamab
How Tocilizumab Prevents CRS with Teclistamab Administration
How Do We Apply T-Cell Redirection for Myeloma? Part 1: Bispecific Antibody Therapies
Bispecific Therapy for High-Risk Smoldering Myeloma
CAR-T Therapy Articles
Raising the BCMA Standard in Multiple Myeloma
The Risk of Secondary Cancers with CAR-T Therapy
The Next Frontier in CAR T-Cell Therapy- GPRC5D: Auto & Allo in the Spotlight
The Effect of Stem Cell Infusion on ICAHT after CAR-T Cell Therapy
Understanding Myeloma Progression, Relapse, and Survival Probability Articles
T-Cell Exhaustion Predicts Early Relapse after SCT in Myeloma
Can You Slow Your Myeloma Progression by Eating a Plant-Based Diet?
Dynamic Frailty Status Could Provide Better Prediction of Survival Probability
Minimal Residual Disease in Myeloma Articles
What Do Myeloma Patients Think About MRD Testing?
Financial and Quality of Life Articles
How Financial Toxicity is Affecting Myeloma Patients and Their Families
Downshifting to Upshift: Changing the Way We Think
Caregiver Distress – How Are You, REALLY?
How Your Insurance Type May Affect Your Blood Cancer Outcome
Finding Renewed Purpose with Myeloma
How Willing Are Black Myeloma Patients to Participate in Clinical Trials?
Groundbreaking Research on Myeloma Treatments
Down with Dex! New Research Reveals Dexamethasone Dosing Can Be Reduced
Using Venetoclax with 11;14 Myeloma Patients
How Can Relapsed/Refractory Myeloma Outcomes Improve in 2024?
Real-World Velcade Prescribing Patterns and Outcomes in Newly Diagnosed Multiple Myeloma
Clinical Investigator Perspectives on the Management of Patients with Multiple Myeloma
High-Risk Smoldering and Active Myeloma Response Articles
How Extramedullary and High-Risk Myeloma Patients Are Responding to Immunotherapy
High-Risk Smoldering Myeloma: To Treat or Not to Treat?
ASH 2023 Resources
Would you like to watch ASH 2023 myeloma research interviews from the investigators themselves? Click "ASH 2023" here: HealthTree University Conference Coverage
To read all of the ASH 2023 articles, click here: HealthTree 2023 ASH Articles
about the author
Audrey Burton-Bethke
Audrey is a content writer and editor for the HealthTree Foundation. She originally joined the HealthTree Foundation in 2020. Audrey loves spending time with her supportive husband, energetic four-year-old, and new baby.
More on Conferences
Trending Articles
Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the Healthtree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:
Education
News Articles Patient Guides My Journal University Expert Webinars Find a Specialist HealthTree PodcastCommunity
Connect Coach Moves All Events Community Support Groups Black Myeloma Health Resources in SpanishCure Hub
HealthTree Cure Hub Find Side Effects Solutions See Tracked Labs Connect Medical Records Treatment Options Twin Machine Clinical Trial FinderFollow Us
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2025 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811